

**Amendment to the claims:**

Please amend the claims as listed in the following listing of claims, which replaces all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

1. (currently amended): A method for delivery and retention of an active agent in one or more targeted lymph nodes, comprising:
  - a) injecting into a mammal a first composition comprising a ligand conjugated to a colloidal particle comprising a diameter of less than 500 nm; and
  - b) injecting into said mammal a second composition comprising an anti-ligand, wherein said anti-ligand binds to said ligand, prior to entering the lymph node wherein the active agent is bound to or encapsulated in either said colloidal particle or said anti-ligand, and wherein the anti-ligand aggregates with the colloid-ligand complex at, or just prior to reaching, the one or more targeted lymph nodes.
2. (currently amended): The method of claim 1, wherein the colloidal particle comprises a liposome.
3. (original): The method of claim 2, wherein the liposome comprises phospholipid.
4. (original): The method of claim 2, wherein the liposome comprises cholesterol.
5. (original): The method of claim 3, wherein the phospholipid comprises DPPC or DSPC.
6. (original): The method of claim 1, wherein the ligand comprises biotin.
7. (original): The method of claim 1, wherein the anti-ligand comprises avidin.
8. (currently amended): The method of claim 1, wherein the colloidal particle is associated with an encapsulates or is bound to the active agent.

9. (currently amended): The method of claim [[8]] 1, wherein the active agent is chosen from the group consisting of diagnostic agents, therapeutic agents, photoactivated dyes, cytotoxic agents, biological response modifiers, hormone suppressants, prodrugs, dyes for visual detection, radiosensitizers, radioprotectors, DNA, RNA, antigens, radioisotopes and neutron capture isotopes.
10. (original): The method of claim 9, wherein the active agent is chosen from the group consisting of radioisotopes and dyes.
11. (original): The method of claim 9, wherein the active agent is chosen from the group consisting of diagnostic agents and dyes for visual detection.
12. (original): The method of claim 9, wherein the active agent is chosen from the group consisting of photoactivated dyes, cytotoxic agents, biological response modifiers, hormone suppressants, prodrugs, radiosensitizers, radioprotectors, DNA, RNA, and neutron capture agents.
13. (currently amended): The method of claim 1, wherein the anti-ligand ~~comprises an~~ is bound to said active agent.
14. (original): The method of claim 1, wherein the ligand comprises biotin and the anti-ligand comprises avidin.
15. (currently amended): A method for detecting one or more sentinel lymph nodes comprising:
  - a) ~~injecting in the vicinity of a tumor in~~ into a mammal a first composition comprising a ligand conjugated to a colloidal particle comprising a diameter of less than 500nm; and
  - b) injecting into said mammal a second composition comprising anti-ligand, wherein said anti-ligand binds to said ligand,

wherein a radioisotope or a dye is bound to or encapsulated in either said colloidal particle or said anti-ligand, and wherein the anti-ligand aggregates with the colloid-ligand complex at, or just prior to reaching, the one or more sentinel lymph nodes.

16. (currently amended): The method of claim 15, wherein the colloidal particle ~~comprises an active agent~~ encapsulates the radioisotope or dye.
17. (currently amended): The method of claim 16, wherein the ~~active agent is chosen from the group consisting of radioisotopes and dyes~~ colloidal particle encapsulates the radioisotope.
18. (currently amended): The method of claim 15, wherein the anti-ligand ~~comprises a detection agent~~ is bound to said radioisotope or dye.
19. (currently amended): The method of claim 18, wherein the ~~detection agent comprises a radioisotope or~~ anti-ligand is bound to said radioisotope dye.

Claims 20-28 (cancelled).

29. (previously presented): The method of claim 9, wherein the active agent comprises a radioisotope and a dye.
30. (currently amended): The method of claim 16, wherein the ~~active agent~~ detection agent comprises a radioisotope and a dye.
31. (canceled).
32. (currently amended): The method of claim ~~[[31]]~~ 1 , wherein the colloidal particle comprises a size range of 5 to 500 nm.

33. (currently amended): The method of claim 32, wherein the colloidal particle comprises a size range of 50 to 300 nm.
34. (previously presented): The method of claim 1, wherein the first and second compositions are administered by subcutaneous, subdermal, submucosal, intraperitoneal, intrapleural, intraarticular, intramucosal, intramuscular, intradermal, intratumoral, interstitial, intraorgan, intracavitary, intralymphatic, intralesion, or intraosseal injection.
35. (canceled).
36. (currently amended): The method of claim [[35]] 15, wherein the colloidal particle comprises a size range of 5 to 500 nm.
37. (currently amended): The method of claim 36, wherein the colloidal particle comprises a size range of 50 to 300 nm.
38. (previously presented): The method of claim 15, wherein the first and second compositions are administered by subcutaneous, subdermal, submucosal, intraperitoneal, intrapleural, intraarticular, intramucosal, intramuscular, intradermal, intratumoral, interstitial, intraorgan, intracavitary, intralymphatic, intralesion, or intraosseal injection.
39. (new): The method of claim 1, further comprising massaging a site of the injection.
40. (new): The method of claim 39, wherein the injection site is massaged for at least 5 minutes.